Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "BMS"

29 News Found

Eugia Pharma receives USFDA approval for Dasatinib Tablets
Drug Approval | April 24, 2025

Eugia Pharma receives USFDA approval for Dasatinib Tablets

Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia


Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
News | February 15, 2025

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab


Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024
News | November 14, 2024

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS


Enzene appoints new site lead of biologics manufacturing
People | September 04, 2024

Enzene appoints new site lead of biologics manufacturing

He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site


Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024
News | August 27, 2024

Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024

New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases


Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Drug Approval | June 22, 2024

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types


Bristol Myers Squibb completes acquisition of Karuna Therapeutics
News | March 21, 2024

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia


Mandaviya interacts with representatives of private medical colleges
News | January 06, 2023

Mandaviya interacts with representatives of private medical colleges

Seeks partnership between government and private medical colleges for providing superior medical education


Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
People | December 20, 2022

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund


Alembic receives USFDA tentative approval for Dasatinib tablets
Drug Approval | June 12, 2022

Alembic receives USFDA tentative approval for Dasatinib tablets

Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive